Resources

Tocilizumab for Hospitalized Patients with COVID-19

Product: — Science Table

Drug Interventions Hospital Care Treatments

covid19-sciencetable.ca Last Updated: March 1, 2021

Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19

Product: — Science Table

Drug Interventions Infectious Diseases & Clinical Care Treatments

covid19-sciencetable.ca Last Updated: February 25, 2021

COVID-19 Outcomes For Priority Populations And Settings

Product: — Evidence Synthesis Network

Health Inequities Low SES Vulnerable Groups Vulnerable Sub-populations

esnetwork.ca Last Updated: February 22, 2021

Remdesivir: Evidence Review and Appraisal

Product: — Canadian Agency for Drugs and Technologies in Health

Drug Interventions Treatments

covid.cadth.ca Last Updated: February 19, 2021

Also available in Français

Ivermectin for the Treatment and Prevention of COVID-19

Product: — Canadian Agency for Drugs and Technologies in Health

Drug Interventions Treatments

covid.cadth.ca Last Updated: February 17, 2021

Also available in Français

Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19

Product: — Cochrane Library

Drug Interventions Treatments

www.cochranelibrary.com Last Updated: February 12, 2021

Also available in Français

Low Molecular Weight Heparin for Thromboprophylaxis of COVID‑19 Positive Long-Term Care Home Residents

Product: — Evidence Synthesis Network

Drug Interventions Long-term & Community Care Long-term Care Treatments

esnetwork.ca Last Updated: February 11, 2021

COVID-19 and Ontario’s Long-Term Care Homes

Product: — Science Table

Health Status Long-term & Community Care Long-term Care Vulnerable Groups

covid19-sciencetable.ca Last Updated: January 20, 2021

Bamlanivimab Implementation Panel

Product: — Canadian Agency for Drugs and Technologies in Health

Drug Interventions Treatments

covid.cadth.ca Last Updated: January 14, 2021

Also available in Français

Bamlanivimab in the Treatment of Outpatients With COVID-19: A Critical Appraisal of an Interim Analysis of the BLAZE-1 Trial

Product: — Canadian Agency for Drugs and Technologies in Health

Drug Interventions Treatments

covid.cadth.ca Last Updated: January 12, 2021

Also available in Français